NASDAQ:CLLSCellectis Stock Price, Forecast & News

Cellectis' stock was trading at $11.43 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, CLLS shares have increased by 48.0% and is now trading at $16.92. View which stocks have been most impacted by Coronavirus.

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Cellectis in the last year. There are currently 1 sell rating, 1 hold rating and 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Cellectis.

Cellectis is scheduled to release its next quarterly earnings announcement on Tuesday, August 4th 2020. View our earnings forecast for Cellectis.

Cellectis SA (NASDAQ:CLLS) released its quarterly earnings results on Wednesday, May, 6th. The biotechnology company reported $0.47 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.59) by $1.06. The biotechnology company earned $51.91 million during the quarter, compared to the consensus estimate of $21.07 million. Cellectis had a negative return on equity of 17.60% and a negative net margin of 93.27%. View Cellectis' earnings history.

7 brokerages have issued 1-year price targets for Cellectis' shares. Their forecasts range from $11.00 to $73.00. On average, they expect Cellectis' share price to reach $32.50 in the next year. This suggests a possible upside of 92.1% from the stock's current price. View analysts' price targets for Cellectis.

Media headlines about CLLS stock have been trending very negative this week, InfoTrie Sentiment Analysis reports. InfoTrie identifies positive and negative news coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Cellectis earned a news impact score of -3.6 on InfoTrie's scale. They also gave media stories about the biotechnology company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an effect on the company's share price in the next few days. View the latest news about Cellectis.

Cellectis saw a decrease in short interest in June. As of June 30th, there was short interest totaling 256,900 shares, a decrease of 16.9% from the June 15th total of 309,200 shares. Based on an average daily volume of 208,700 shares, the short-interest ratio is currently 1.2 days. Approximately 0.6% of the company's shares are short sold. View Cellectis' Current Options Chain.

Some companies that are related to Cellectis include Fate Therapeutics (FATE), Denali Therapeutics (DNLI), Twist Bioscience (TWST), Immunovant (IMVT), Alector (ALEC), Editas Medicine (EDIT), Bill.com (RVMD), Forma Therapeutics (FMTX), Sorrento Therapeutics (SRNE), Adverum Biotechnologies (ADVM), SpringWorks Therapeutics (SWTX), Sangamo Therapeutics (SGMO), Mesoblast (MESO), Legend Biotech (PCVX) and Regenxbio (RGNX). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Cellectis investors own include Calyxt (CLXT), NVIDIA (NVDA), Gilead Sciences (GILD), Editas Medicine (EDIT), Advanced Micro Devices (AMD), Crispr Therapeutics (CRSP), Micron Technology (MU), Intellia Therapeutics (NTLA), Sarepta Therapeutics (SRPT) and Alibaba Group (BABA).

(CLLS) raised $129 million in an IPO on Wednesday, March 25th 2015. The company issued 3,500,000 shares at a price of $36.83 per share. BofA Merrill Lynch, Jefferies and Piper Jaffray acted as the underwriters for the IPO and Oppenheimer was co-manager.

Cellectis trades on the NASDAQ under the ticker symbol "CLLS."

Cellectis' stock is owned by many different institutional and retail investors. Top institutional shareholders include Envestnet Asset Management Inc. (0.16%).

CLLS stock was acquired by a variety of institutional investors in the last quarter, including Envestnet Asset Management Inc..

Shares of CLLS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of CLLS stock can currently be purchased for approximately $16.92.

Cellectis has a market capitalization of $718.52 million and generates $22.99 million in revenue each year. The biotechnology company earns $-102,090,000.00 in net income (profit) each year or ($2.41) on an earnings per share basis. Cellectis employs 161 workers across the globe.

The official website for Cellectis is www.cellectis.com.

Cellectis' mailing address is 8 RUE DE LA CROIX JARRY, PARIS I0, 75013. The biotechnology company can be reached via phone at 33-1-81-69-16-00 or via email at [email protected]